基于纳米颗粒的丙型肝炎疫苗效力增强
研究设计并制备了sE2-ferritin融合蛋白纳米颗粒疫苗,在果蝇S2细胞中表达自组装,sE2展示于表面。小鼠免疫显示其诱导抗HCV广谱中和抗体效力优于未融合sE2,sE2部分具近天然构象且亲和力更高。
要点
- sE2-ferritin纳米颗粒疫苗在小鼠中诱导广谱中和抗体效力优于sE2。
- 纳米颗粒表面sE2具近天然构象,对中和抗体、受体和患者血清亲和力更高。
- 该疫苗候选为控制HCV提供新可能,但尚需进一步临床验证。
核心结论
- sE2-ferritin纳米颗粒是优于既往sE2的疫苗候选,为控制HCV提供新可能。
研究设计与样本
- 在果蝇S2细胞中设计并生产sE2-ferritin融合蛋白,自组装为表面展示sE2的纳米颗粒。
主要发现
- sE2-ferritin纳米颗粒上sE2部分具近天然构象,对中和抗体、受体和患者血清亲和力优于未融合sE2。
- 小鼠免疫研究中sE2-ferritin诱导抗HCV广谱中和抗体的效力高于sE2。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite the emergence of new direct-acting antivirals, hepatitis C virus (HCV) chronic infection and its consequent fibrosis and hepatocarcinoma remain a significant burden for public health, thus requiring an effective preventive vaccine. Our group previously showed that a subunit vaccine based on recombinant soluble E2 (sE2) can induce broadly neutralizing antibodies. To improve the immunogenicity of sE2, we designed and produced a fusion protein (sE2-ferritin) comprising sE2 and a ferritin unit in Drosophila S2 cells, which self-assembled into a nanoparticle with sE2 displayed on the surface. The sE2 moiety on the sE2-ferritin nanoparticle not only had nearly natural conformation but also had better affinities than the unfused sE2 to neutralizing antibodies, receptor, and patient serum. Mouse immunization studies showed that sE2-ferritin was more potent than sE2 in inducing anti-HCV broadly neutralizing antibodies. Our results demonstrate that sE2-ferritin is a vaccine candidate superior to previously developed sE2, providing a new possibility for controlling HCV.
引用
- Yan Y, Wang X, Lou P, et al. A Nanoparticle-Based Hepatitis C Virus Vaccine With Enhanced Potency. J Infect Dis. 2020. PMID: 31074790. doi:10.1093/infdis/jiz228
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。